The 3,600 sqft facility will help develop the MIMIX sustained-release intradermal microneedle patch, which is planned for proof-of-concept trials for COVID-19 in 2022
Get your tickets before 10 February and save £50 before our early bird rate ends.
Get breaking news, product releases, technical papers, innovation features, trend reports and live content agendas covering the entire industry.